Soleno Therapeutics Inc

NASDAQ:SLNO   4:00:00 PM EDT
86.21
+3.58 (+4.33%)
6:04:22 PM EDT: $84.46 -1.75 (-2.03%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)4.34B
Current PEN/A
Forward PE N/A
2yr Forward PE 80.57
See more stats
Estimates Current Quarter
Revenue$3.91 Million
Adjusted EPS-$0.81
See more estimates
10-Day MA$83.01
50-Day MA$77.13
200-Day MA$58.20
See more pivots

Soleno Therapeutics Inc Stock, NASDAQ:SLNO

100 Marine Parkway, Suite 400, Redwood City, California 94065
United States of America
Phone: +1.650.213.8444
Number of Employees: 92

Description

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.